Search the Newsreel

Equities Analysts Set Expectations for Nkarta Q3 Earnings

Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside

Nkarta, Inc. (NKTX) has seen its average 12-month price target cut to $11 from $11.33 by analysts, with forecasts ranging from $9 to $14 per share. This updated target suggests a potential upside of approximately 347% based on the recent closing price. The consensus …

H.C. Wainwright cuts Nkarta stock price target on trial progress

H.C. Wainwright lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $14 from $16, while maintaining a Buy rating. The firm's decision followed Nkarta's Q2 2026 earnings report and an update on its Ntrust-1 and Ntrust-2 trials for NKX019 in autoimmune diseases, with initial …

Nkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019

(RTTNews) - Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed to higher operating expenses and lower other income. The company has also provided a clinical update on …

Nkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary

Nkarta, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, states that unlimited access to the full content requires a TradingView subscription.

Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Nkarta (NASDAQ:NKTX) reported a quarterly loss of $0.54 per share, missing the consensus estimate by $0.18. Despite the earnings miss, NKTX shares rose 2.1% to $2.46 in midday trading. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price …

Nkarta Q2 Results: Net loss widens to $40.4M, cash funds ops to 2029

Nkarta, a biotechnology company, reported a Q2 2026 net loss of $40.4 million, or $(0.54) per share, significantly missing analyst estimates and widening from the previous year. This increase is attributed to higher operating expenses, particularly in general and administrative costs. Despite the loss, …

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Nkarta, Inc. reported its second quarter 2026 financial results, highlighting continued enrollment in its Ntrust-1 and Ntrust-2 clinical trials for autoimmune diseases at the 4 billion cell dose level, with initial data expected in 2026. The company also announced that its cash balance of …

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts

Nkarta, Inc. (NASDAQ:NKTX) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month price target of $10.75, significantly above its current share price of $2.41. The company reported a quarterly loss of $0.37 per share, beating analyst estimates. Institutional investors …

Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Nkarta Inc (NKTX) has an earnings forecast score of 8.67, ranking 75th in its industry. Analysts have set an average price target of $11.00, with a high of $16.00 and a low of $8.00, predominantly recommending a "Buy" for the stock. The company's EPS …

Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday

Nkarta (NKTX) is scheduled to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts projecting a loss of $0.39 per share. The company previously exceeded estimates in Q1 by reporting a loss of $0.37 per share. NKTX shares are …

NKTX|Nkarta Inc|Price:2.090|Chg%:-0.060

This article provides a detailed stock analysis of Nkarta Inc (NKTX), highlighting its weak fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price of …

Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nkarta Inc (NKTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that NKTX is suitable for range-bound swing trading, with most indicators signaling "Sell" or "Oversold," and …

Nkarta, Inc. Revenue Breakdown – NASDAQ:NKTX

This article provides a brief overview of Nkarta, Inc. (NASDAQ: NKTX), focusing on its financial data and revenue breakdown. It points to the company's financials page on TradingView, indicating where users can find statements, statistics, dividends, earnings, and segment information. The content itself seems …

Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Nkarta Inc (NKTX), detailing its volatility, financial risks, and investment risks. It highlights the company's beta value of 0.92, indicating it tends to underperform in up markets but decline less in down markets. The assessment also includes …

Nkarta Inc (NKTX) Institutional Confidence

Nkarta Inc (NKTX) has an institutional shareholding score of 7.00, placing it 80th out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 82.11%, a decrease of 4.32% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.43% of …

Nkarta Market Sentiment

This article provides an overview of market sentiment for Nkarta (NKTX), including analyst consensus, short interest, options flow, and insider activity. The analysis indicates a "Buy" consensus from analysts, a 5.9% declining short float, and a bullish options flow. The piece also details recent …

Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Nkarta Inc's (NKTX) financial health, indicating a weak financial status and low operating efficiency. The company's financial score is 5.46, ranking 353 out of 386 in the Biotechnology & Medical Research industry, with critical data points like total …

Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Nkarta Inc (NKTX), outlining both major shareholders and institutional holdings. It provides a breakdown of significant holders like RA Capital Management and New Enterprise Associates, along with the proportion of shares they own. The report also categorizes …

Nkarta Inc (NKTX) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Nkarta Inc (NKTX), covering operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering insight into the company's financial health and performance over time. The document also includes …